These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

735 related items for PubMed ID: 31210417

  • 1. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS, Chen WH, Liu SL, Liang YJ, Chen QY, Guo SS, Wen YF, Liu LT, Xie HJ, Tang QN, Li XY, Yan JJ, Mai HQ, Tang LQ.
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [Abstract] [Full Text] [Related]

  • 2. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R, Tang LL, Mao YP, Du XJ, Chen L, Zhang ZC, Liu LZ, Tian L, Luo XT, Xie YB, Ren J, Sun Y, Ma J.
    Cancer; 2019 Jan 01; 125(1):79-89. PubMed ID: 30351466
    [Abstract] [Full Text] [Related]

  • 3. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy.
    Ji P, Lu Q, Chen X, Chen Y, Peng X, Chen Z, Lin C, Lin S, Zong J.
    Cancer Res Treat; 2023 Oct 01; 55(4):1113-1122. PubMed ID: 37170497
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
    Lee VH, Kwong DL, Leung TW, Choi CW, O'Sullivan B, Lam KO, Lai V, Khong PL, Chan SK, Ng CY, Tong CC, Ho PP, Chan WL, Wong LS, Leung DK, Chan SY, So TH, Luk MY, Lee AW.
    Int J Cancer; 2019 Apr 01; 144(7):1713-1722. PubMed ID: 30192385
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB, Zhang N, Chen DM, Yang XL, Chen BH, Zhao H, Lu RL, Chen Y, Fu LW.
    Radiother Oncol; 2019 Mar 01; 132():223-229. PubMed ID: 30366725
    [Abstract] [Full Text] [Related]

  • 8. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
    Chen WH, Tang LQ, Guo SS, Chen QY, Zhang L, Liu LT, Qian CN, Guo X, Xie D, Zeng MS, Mai HQ.
    Medicine (Baltimore); 2016 Feb 01; 95(5):e2642. PubMed ID: 26844482
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [18 F]-fluorodeoxyglucose positron emission tomography.
    Xie HJ, Yu YF, Sun XS, Jia GD, Luo DH, Sun R, Liu LT, Guo SS, Liu SL, Chen QY, Tang LQ, Mai HQ.
    Cancer Med; 2020 Dec 01; 9(23):8852-8863. PubMed ID: 33034945
    [Abstract] [Full Text] [Related]

  • 12. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
    Liu SL, Sun XS, Xie HJ, Chen QY, Lin HX, Liang H, Liang YJ, Li XY, Yan JJ, Lin C, Yang ZC, Guo SS, Liu LT, Tang QN, Du YY, Tang LQ, Guo L, Mai HQ.
    BMC Cancer; 2020 Feb 03; 20(1):89. PubMed ID: 32013967
    [Abstract] [Full Text] [Related]

  • 13. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
    Sun XS, Liu SL, Liang YJ, Chen QY, Li XY, Tang LQ, Mai HQ.
    Cancer Commun (Lond); 2020 Jan 03; 40(1):32-42. PubMed ID: 32112522
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
    Hua L, Chen S, Wei M, Shen Y, Long J, Lin Z, Meng Y, Guo C, Huang H, Tu X, Yao M.
    Cancer Biother Radiopharm; 2022 Feb 03; 37(1):2-10. PubMed ID: 33764811
    [Abstract] [Full Text] [Related]

  • 19. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
    Zhang J, Peng H, Li WF, Zhang Y, Liu LZ, Tian L, Lin AH, Sun Y, Ma J.
    BMC Cancer; 2018 Dec 19; 18(1):1276. PubMed ID: 30567511
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.